Document Detail

Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities.
MedLine Citation:
PMID:  15022328     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To evaluate whether serum matrix metalloproteinase 9 (MMP-9) levels are associated with neuropsychiatric manifestations, particularly cognitive dysfunction, as evaluated by neuropsychological testing and brain magnetic resonance imaging (MRI) abnormalities in patients with systemic lupus erythematosus (SLE). METHODS: MMP-9 determinations were made in 44 patients with SLE and 43 healthy controls who underwent a clinical neurologic and neuropsychological investigation in order to identify neuropsychiatric manifestations. Cerebral MRI scans with volumetric estimation of intracranial cerebrospinal fluid spaces, T1-weighted lesions, and T2-weighted lesions were performed for all subjects. SLE activity was assessed by the European Consensus Lupus Activity Measure (ECLAM) index, and accumulated neuropsychiatric abnormality was assessed by the Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology damage index. RESULTS: No significant difference was found in serum MMP-9 levels between the overall group of SLE patients and controls. However, SLE patients who had at least 1 neuropsychiatric manifestation (NPSLE patients) had significantly higher serum MMP-9 concentrations than did SLE patients without neuropsychiatric syndromes (P = 0.009). Among patients with NPSLE, those with cognitive deficits had significantly higher concentrations of serum MMP-9 than did those with normal cognitive function (P = 0.027). Furthermore, serum MMP-9 levels had a significant positive correlation with the volumes of T1-weighted and T2-weighted lesions in the brain MRI (P = 0.031 and P = 0.015, respectively). The concentration of serum MMP-9 correlated significantly with the SLICC index but not with the ECLAM index. CONCLUSION: Elevated levels of serum MMP-9 in patients with SLE may reflect neuropsychiatric involvement, particularly cognitive dysfunction. The serum MMP-9 concentration may be associated with small- vessel cerebral vasculopathy and increased risk of cerebral ischemic events in patients with SLE.
Hanna Ainiala; Aki Hietaharju; Prasun Dastidar; Jukka Loukkola; Terho Lehtimäki; Jukka Peltola; Markku Korpela; Tomi Heinonen; Seppo T Nikkari
Related Documents :
7507728 - Increased frequency of ngf in sera of rheumatoid arthritis and systemic lupus erythemat...
20436078 - Brachial artery endothelial-dependent flow-mediated dilation identifies early-stage end...
7091158 - A prospective study of raynaud phenomenon and early connective tissue disease. a five-y...
19747218 - Ccl13 is a promising diagnostic marker for systemic sclerosis.
23000298 - Non-homogeneous effect of levodopa on inhibitory circuits in parkinson's disease and dy...
2112218 - Reducing sick leave costs by shortening waiting periods for elective surgery.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Arthritis and rheumatism     Volume:  50     ISSN:  0004-3591     ISO Abbreviation:  Arthritis Rheum.     Publication Date:  2004 Mar 
Date Detail:
Created Date:  2004-03-15     Completed Date:  2004-04-09     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0370605     Medline TA:  Arthritis Rheum     Country:  United States    
Other Details:
Languages:  eng     Pagination:  858-65     Citation Subset:  AIM; IM    
Department of Neurology and Rehabilitation, Tampere University Hospital, Tampere, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Antinuclear / analysis
Brain / pathology*
Case-Control Studies
DNA / immunology
Lupus Erythematosus, Systemic / blood*,  complications*,  diagnosis,  therapy
Magnetic Resonance Imaging*
Matrix Metalloproteinase 9 / blood*
Mental Disorders / etiology*
Middle Aged
Nervous System Diseases / etiology*
Reg. No./Substance:
0/Antibodies, Antinuclear; 9007-49-2/DNA; EC Metalloproteinase 9
Comment In:
Arthritis Rheum. 2005 Feb;52(2):673-4; author reply 674   [PMID:  15692966 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis.
Next Document:  Is alpha-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis?